Neoadjuvant Therapy Fundamental in TNBC and HER2+ Breast Cancer
March 19th 2017Neoadjuvant therapy in early breast cancer has evolved during the past 2 decades from use primarily in large inoperable tumors to a standard treatment option for patients with early-stage HER2-positive and triple-negative breast cancer.
Expert Examines Clues to Deploying Immunotherapy in Breast Cancer
March 18th 2017Immunotherapy will be most effective as a treatment for breast cancer when it is used to alter the tumor microenvironment, according to a careful examination of studies exploring the immune response presented by Nora Disis, MD.
Combination Approaches Combat Resistance to Endocrine Therapy in HR+ Breast Cancer
March 17th 2017Genomic studies have made significant advancements in discovering methods to combat resistance to endocrine therapy in patients with hormone receptor (HR)–positive breast cancer over the past few years, according to Ian E. Krop, MD, PhD. Of particular interest are combination therapies blocking multiple driver pathways and resistance mechanisms.
Ribociclib Response Unaffected by Prior Treatment
March 17th 2017Updated findings from the MONALEESA-2 trial demonstrated that the response to ribociclib (Kisqali) in postmenopausal women with hormone-receptor-positive/HER2-negative advanced or metastatic breast cancer was unaffected by either prior endocrine treatment or prior chemotherapy.
Dr. Osborne Discusses the Future of Treatment in HER2+ Breast Cancer
March 16th 2017C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.